Amgen

Neumora Therapeutics stock surges as Amgen confirmed as major shareholder
Neumora Therapeutics stock surges as Amgen confirmed as major shareholder
Proactive Investors
Amgen
Neumora
IPOs
Flag link:
Amgen unveils Partners of Choice oncology network
Amgen unveils Partners of Choice oncology network
Medical Marketing and Media
Amgen
expert panels
oncology
cancer
Flag link:
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans
BioSpace
Amgen
Horizon Therapeutics
FTC
antitrust
M&A
Flag link:
FTC allows Amgen’s $27.8B purchase of Horizon to proceed
FTC allows Amgen’s $27.8B purchase of Horizon to proceed
Medical Marketing and Media
FTC
Amgen
Horizon Therapeutics
M&A
Flag link:
FTC Temporarily Withdraws Challenge to $27.8B Amgen-Horizon Deal
FTC Temporarily Withdraws Challenge to $27.8B Amgen-Horizon Deal
BioSpace
FTC
Amgen
Horizon Therapeutics
M&A
Flag link:
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
BioSpace
Amgen
cardiovascular disease
olpasiran
clinical trials
Flag link:
'Far too speculative': Amgen fights FTC's request for injunction against $28B Horizon merger
'Far too speculative': Amgen fights FTC's request for injunction against $28B Horizon merger
Fierce Pharma
Amgen
Horizon Therapeutics
M&A
FTC
Flag link:
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
BioSpace
patent cliff
patents
Takeda
Vyvanse
Pfizer
Eraxis
JNJ
Stelara
Merck
Isentress
Eiger Pharmaceuticals
Zokinvy
Astellas
Myrbetriq
Novartis
Entresto
Amgen
Otzela
Flag link:
KRAS crisis? FDA will gather advisers to weigh full approval for Amgen's Lumakras
KRAS crisis? FDA will gather advisers to weigh full approval for Amgen's Lumakras
Fierce Pharma
Amgen
Lumakras
KRAS inhibitors
FDA
Flag link:
The 10 drugs that CMS might wrangle into negotiations
The 10 drugs that CMS might wrangle into negotiations
Beckers Hospital Review
CMS
Medicare
drug pricing
Bristol Myers Squibb
Janssen
Merck
Pfizer
Amgen
Boehringer Ingelheim
Pharmacyclics
AstraZeneca
Astellas
GSK
Flag link:
Mirati CEO Steps Down After Going Toe-to-Toe with Amgen in KRAS
Mirati CEO Steps Down After Going Toe-to-Toe with Amgen in KRAS
BioSpace
Mirati Therapeutics
Pharma CEOs
David Meek
Amgen
KRAS inhibitors
Flag link:
Amgen Clinches Clinical Wins in SCLC and Colorectal Cancer
Amgen Clinches Clinical Wins in SCLC and Colorectal Cancer
BioSpace
Amgen
oncology
colorectal cancer
small cell lung cancer
tarlatamab
Lumakras
Flag link:
Amgen's hyped Humira biosimilar fritters away its exclusivity advantage
Amgen's hyped Humira biosimilar fritters away its exclusivity advantage
Fierce Pharma
Amgen
AbbVie
biosimilars
Humira
Flag link:
Amgen's tarlatamab BiTEs at small cell lung cancer in brief readout
Amgen's tarlatamab BiTEs at small cell lung cancer in brief readout
Fierce Biotech
Amgen
tarlatamab
small cell lung cancer
T-cells
Flag link:
Biosimilar makers split strategies in bid to take on top-selling Humira
Biosimilar makers split strategies in bid to take on top-selling Humira
BioPharma Dive
biosimilars
Humira
AbbVie
rebates
drug pricing
Amgen
Celltrion
Novartis
Boehringer Ingelheim
Biocon
Fresenius
Sandoz
Organon
Coherus
Flag link:
AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis
AbbVie's Skyrizi delivers head-to-head win versus Amgen's Otezla in psoriasis
Fierce Pharma
AbbVie
Skyrizi
Amgen
Otezla
Boehringer Ingelheim
psoriasis
Flag link:
Amgen’s lupus bets continue to flounder, even those on the Horizon
Amgen’s lupus bets continue to flounder, even those on the Horizon
Fierce Biotech
Horizon Therapeutics
Amgen
lupus
daxdilimab
clinical trials
Flag link:
FTC, Amgen Break Off Settlement Talks Over Horizon Deal
FTC, Amgen Break Off Settlement Talks Over Horizon Deal
BioSpace
Amgen
Horizon Therapeutics
M&A
FTC
Flag link:
Biopharma buyouts bounce back
Biopharma buyouts bounce back
EP Vantage
M&A
Amgen
Astellas
Eli Lilly
GSK
Horizon Therapeutics
Merck
Novartis
Pfizer
Seagen
Flag link:
States Back FTC in Lawsuit Seeking to Block Amgen-Horizon Deal
States Back FTC in Lawsuit Seeking to Block Amgen-Horizon Deal
BioSpace
Amgen
Horizon Therapeutics
M&A
FTC
Flag link:

Pages